Skip to Content


In the US, Octreotide (octreotide systemic) is a member of the drug class somatostatin and somatostatin analogs and is used to treat Acromegaly, Carcinoid Tumor, Diabetes - Type 1, Diarrhea, Dumping Syndrome, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Postural Orthostatic Tachycardia Syndrome, Small Bowel or Pancreatic Fistula and Vasoactive Intestinal Peptide Tumor.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Hemostatic agent, gastrointestinal tract

Growth hormone release inhibiting hormone analogue (analogue of somatostatin)

Chemical Name

D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-treonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymetyl)propyl]-L-cysteinamido cyclic (2-7) disulfide

Foreign Names

  • Octreotidum (Latin)
  • Octreotid (German)
  • Octréotide (French)
  • Octreotida (Spanish)

Generic Names

Brand Names


BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.